

06 May 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Japan's Ono buys US oncology firm; strong growth but supply issues for Lilly; Novo and Lilly make their money work; BMS cuts jobs, costs; and Big Pharma's support for bioventures.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 3 May 2024, including: Japan's [\*Ono Pharmaceutical Company, Ltd.\*](#) buys US oncology firm; strong growth but supply issues for [\*Eli Lilly and Company\*](#); [\*Novo Nordisk A/S\*](#) and Lilly make their money work; [\*Bristol Myers Squibb Company\*](#) cuts jobs, costs; and big pharma's support for bioventures.

This and all our other podcasts are available on the *Citeline* channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure\*](#)" - Scrip, 29 Apr, 2024.)

(Also see "[\*Lilly Mounjaro, Zepbound Supply Issues Persist Amid Strong Growth\*](#)" - Scrip, 30 Apr, 2024.)

(Also see "[\*Analysis: Novo And Lilly Make Their Money Work\*](#)" - Scrip, 26 Apr, 2024.)

(Also see "[\*BMS Will Cut \\$1.5bn And 2,200 Jobs To Reinvest In Needed Growth\*](#)" - Scrip, 25 Apr, 2024.)

(Also see "[\*Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs\*](#)" - Scrip, 1 May, 2024.)

[Click here to explore this interactive content online](#) ✨